QLGN Valuation

Qualigen Therapeutics Inc

Add to Watchlist

Advanced Chart

5.530

+2.69(94.718%)1D

Overview
Forecast
Valuation
Earnings

QLGN Relative Valuation

QLGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, QLGN is overvalued; if below, it's undervalued.

Historical Valuation

Qualigen Therapeutics Inc (QLGN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.91. The fair price of Qualigen Therapeutics Inc (QLGN) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：5.53

Fair

-0.08

Trailing

Forward

0.00

EV/EBITDA

Qualigen Therapeutics Inc. (QLGN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.96

EV/EBIT

Qualigen Therapeutics Inc. (QLGN) has a current EV/EBIT of -0.96. The 5-year average EV/EBIT is -1.06. The thresholds are as follows: Strongly Undervalued below -4.23, Undervalued between -4.23 and -2.65, Fairly Valued between 0.53 and -2.65, Overvalued between 0.53 and 2.11, and Strongly Overvalued above 2.11. The current Forward EV/EBIT of -0.96 falls within the Historic Trend Line -Fairly Valued range.

0.00

Qualigen Therapeutics Inc. (QLGN) has a current PS of 0.00. The 5-year average PS is 3.97. The thresholds are as follows: Strongly Undervalued below -5.71, Undervalued between -5.71 and -0.87, Fairly Valued between 8.81 and -0.87, Overvalued between 8.81 and 13.65, and Strongly Overvalued above 13.65. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Qualigen Therapeutics Inc. (QLGN) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.

0.00

P/FCF

Qualigen Therapeutics Inc. (QLGN) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

Qualigen Therapeutics Inc (QLGN) has a current Price-to-Book (P/B) ratio of -1.05. Compared to its 3-year average P/B ratio of -0.25 , the current P/B ratio is approximately 319.62% higher. Relative to its 5-year average P/B ratio of -0.74, the current P/B ratio is about 40.47% higher. Qualigen Therapeutics Inc (QLGN) has a Forward Free Cash Flow (FCF) yield of approximately -140.33%. Compared to its 3-year average FCF yield of -288.01%, the current FCF yield is approximately -51.28% lower. Relative to its 5-year average FCF yield of -188.80% , the current FCF yield is about -25.67% lower.

-1.05

P/B

Median3y

-0.25

Median5y

-0.74

-140.33

FCF Yield

Median3y

-288.01

Median5y

-188.80

Competitors Valuation Multiple

The average P/S ratio for QLGN's competitors is 0.10, providing a benchmark for relative valuation. Qualigen Therapeutics Inc Corp (QLGN) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

QLGN.O

Qualigen Therapeutics Inc

PharmaCyte Biotech Inc

Loss

46.20M

ENVB.O

Enveric Biosciences Inc

Loss

1.95M

SCNI.O

Scinai Immunotherapeutics Ltd

Performance Decomposition

Market capitalization of QLGN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of QLGN in the past 1 year is driven by Unknown.